文献速递糖尿病

糖尿病神经病变:未来方向何在?

Diabetic neuropathy: what does the future hold?
PubMed 文献 · Diabetologia · 2020-01-23

综述指出糖尿病神经病变仍缺乏改善病情的治疗,血糖控制在1型糖尿病中有预防作用而2型糖尿病中未见;肥胖成为第二重要代谢危险因素,血脂异常和鞘磷脂代谢改变是新兴机制;诊断仍依赖病史和查体,皮肤活检和角膜共聚焦显微镜尚未证明临床效用;治疗方面共识推荐三环类抗抑郁药、5-羟色胺-去甲肾上腺素再摄取抑制剂和加巴喷丁类药物治疗神经病理性疼痛,应优先于阿片类药物。

要点

  • 血糖控制在1型糖尿病中预防神经病变作用明确,在2型糖尿病中未见此效应。
  • 肥胖是神经病变第二重要代谢危险因素,血脂异常和鞘磷脂代谢改变为新兴机制。
  • 共识推荐三环类抗抑郁药、5-羟色胺-去甲肾上腺素再摄取抑制剂和加巴喷丁类药物治疗神经病理性疼痛。

核心结论

  • 糖尿病神经病变仍缺乏改善病情的治疗,但新代谢危险因素和机制提示新策略。

研究设计与样本

  • 综述,汇总七项全球人群观察性研究的共识发现。

主要发现

  • 血糖控制对1型糖尿病个体预防神经病变有强效应,对2型糖尿病个体未见此效应。
  • 肥胖被七项全球观察性研究共识认定为神经病变第二重要代谢危险因素(糖尿病为第一)。
  • 血脂异常和鞘磷脂代谢改变是神经损伤的新兴机制,可能导向新的靶向治疗。
  • 皮肤活检和角膜共聚焦显微镜是有前景的新检测,已用作研究结局指标但尚未证明明确临床效用。
  • 证据支持运动的程度目前超过支持减重的数据。

关键数值与推荐

  • 共识推荐三环类抗抑郁药、5-羟色胺-去甲肾上腺素(去甲肾上腺素)再摄取抑制剂和加巴喷丁类药物治疗神经病理性疼痛。
  • 处方这些药物时应考虑自付费用,因其疗效和耐受性相似。

临床怎么用

  • 临床病史和检查仍是神经病变准确诊断的关键组成部分。
  • 尽管有数据,当前临床实践常在处方指南推荐治疗之前启动并继续阿片类药物用于神经病理性疼痛患者。
  • 阿片类药物治疗慢性非癌性疼痛的弊端日益明显。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive. Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but not in those with type 2 diabetes, which constitute the vast majority of patients. Encouragingly, recent evidence points to new metabolic risk factors and mechanisms, and thus also at novel disease-modifying strategies, which are desperately needed. Obesity has emerged as the second most important metabolic risk factor for neuropathy (diabetes being the first) from consensus findings of seven observational studies in populations across the world. Moreover, dyslipidaemia and altered sphingolipid metabolism are emergent novel mechanisms of nerve injury that may lead to new targeted therapies. Clinical history and examination remain critical components of an accurate diagnosis of neuropathy. However, skin biopsies and corneal confocal microscopy are promising newer tests that have been used as outcome measures in research studies but have not yet demonstrated clear clinical utility. Given the emergence of obesity as a neuropathy risk factor, exercise and weight loss are potential interventions to treat and/or prevent neuropathy, although evidence supporting exercise currently outweighs data supporting weight loss. Furthermore, a consensus has emerged advocating tricyclic antidepressants, serotonin-noradrenaline (norepinephrine) reuptake inhibitors and gabapentinoids for treating neuropathic pain. Out-of-pocket costs should be considered when prescribing these medications since their efficacy and tolerability are similar. Finally, the downsides of opioid treatment for chronic, non-cancer pain are becoming increasingly evident. Despite these data, current clinical practice frequently initiates and continues opioid prescriptions for patients with neuropathic pain before prescribing guideline-recommended treatments.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Callaghan BC, Gallagher G, Fridman V, et al. Diabetic neuropathy: what does the future hold? Diabetologia. 2020. PMID: 31974731. doi:10.1007/s00125-020-05085-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。